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Abstract
Introduction:Developing cross-validatedmulti-biomarkermodels for the prediction of
the rate of cognitive decline in Alzheimer’s disease (AD) is a critical yet unmet clinical
challenge.
Methods: We applied support vector regression to AD biomarkers derived from
cerebrospinal fluid, structural magnetic resonance imaging (MRI), amyloid-PET and
fluorodeoxyglucose positron-emission tomography (FDG-PET) to predict rates of cog-
nitive decline. Prediction models were trained in autosomal-dominant Alzheimer’s dis-
ease (ADAD, n = 121) and subsequently cross-validated in sporadic prodromal AD
(n= 216). The sample size needed to detect treatment effects when usingmodel-based
risk enrichment was estimated.
Results: A model combining all biomarker modalities and established in ADAD pre-
dicted the 4-year rate of decline in global cognition (R2 = 24%) and memory (R2 =
25%) in sporadic AD. Model-based risk-enrichment reduced the sample size required
for detecting simulated intervention effects by 50%–75%.
Discussion: Our independently validated machine-learning model predicted cognitive
decline in sporadic prodromal AD and may substantially reduce sample size needed in
clinical trials in AD.
K EYWORD S
Alzheimer’s disease, autosomal-dominant Alzheimer’s disease, biomarkers, machine learning, pro-
gression prediction, MRI, PET, risk enrichment
1 BACKGROUND
Alzheimer’s disease (AD) is characterized by amyloid-beta (A𝛽) depo-
sition, tau pathology, neurodegeneration, and cognitive decline.1 Diag-
nosing and staging AD has been greatly facilitated by in vivo biomark-
ers including positron-emission tomography (PET) and cerebrospinal
fluid (CSF) markers of A𝛽 and pathologic tau, as well as volumet-
ric magnetic resonance imaging (MRI) and fluorodeoxyglucose (FDG)-
PET measures of neurodegeneration.2 Apart from diagnosing AD, a
clinically important challenge is predicting the worsening of cognitive
impairment.3
Previous studies have shown that markers of primary AD pathol-
ogy (ie, CSF A𝛽1-42, p-tau181, A𝛽1-42/p-tau181 ratio, amyloid-PET), neu-
rodegeneration (structural MRI, FDG-PET), or biomarker combina-
tions can predict future conversion from mild cognitive impairment
(MCI) to AD dementia.4–9 The conversion from MCI to AD dementia
is, however, a binary diagnostic categorization that does not capture
the rate of cognitive change within the AD continuum.10 Biomarker-
based point prediction of cognitive decline is, thus, a challenge to
sufficiently power clinical trials via risk enrichment and to identify
subjects at imminent risk of cognitive deterioration. Previous studies
have shown that higher amyloid-PET,11,12 MRI-assessed hippocampal
atrophy,13 FDG-PET hypometabolism,12 and tau levels14,15 are asso-
ciated with faster cognitive decline. Because biomarker combinations
can enhance the accuracy for predicting clinical progression,16 a crit-
ical yet unresolved question is how to merge multimodal and increas-
ingly complex (eg, voxel-wise PET and MRI) data to maximize the pre-
diction accuracy while keeping the number of assessments and costs
low. Machine learning, which is instrumental for data mining,17 is well
suited to identify biomarker sets for predicting cognitive decline. Here,
recent machine-learning approaches to AD biomarker data showed
that sets of imaging and CSF-derived markers discriminated MCI and
AD patients from healthy controls18 and predicted the rate of future
cognitive decline19,20 and time to symptom onset.21
A limitation of machine learning is, however, that algorithms may
perform well in the sample they were trained on but rarely general-
ize to new data.22,23 To address this, previous studies have applied
within-sample cross-validation (CV), in which a given sample is itera-
tively divided into training and test data to ensure that model train-
ing and testing are conducted on different datasets.18,24 While reduc-
ing the likelihood of overfitting, this approach leaves unaddressed the
question whether the algorithm indeed generalizes to new and unseen
data from independently recruited participants,25 which is considered
the gold standard of evaluatingmachine-learning performance.
Here, we aimed to establish a biomarker-based model to predict
AD-related cognitive change rates, using validation across two inde-
pendently recruited, deeply phenotyped AD samples. To this end, we
first trained and cross-validated a support vector regression (SVR)
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model using amyloid-PET, FDG-PET, structuralMRI, andCSF data from
121autosomal-dominantAlzheimer’s disease (ADAD) subjects for pre-
dicting the estimated years to symptom onset (EYO), a proxy of cogni-
tive decline. ADAD constitutes a unique training sample as the disease
onset is at a relatively young age and the development of AD pathol-
ogy and cognitive decline are not confounded by age-related comor-
bidities (eg, TDP-43, small-vessel disease).26 Because inADADthe time
course of the development of dementia symptoms is strongly geneti-
cally driven, EYO can be used as a surrogatemarker of AD-related cog-
nitive decline.27–29 Here, we first trained biomarker-based machine-
learning models for predicting EYO in ADAD. After model training and
CV in ADAD, we tested whether the best model predicts up to 4-year
cognitive decline when applied to an independent sample of 216 indi-
viduals with sporadic prodromal AD. Last, we tested whether machine
learning–based selection of “at-risk” subjects can enhance the sensitiv-
ity to detect potential intervention effects and can reduce the required
sample size in intervention studies.
2 METHODS
2.1 Participants
2.1.1 Dominantly Inherited Alzheimer Network
(DIAN)
We included 121 carriers of AD causative PSEN1 and 2 or APP muta-
tions (MC, data freeze 10), as well as 54 non-carrier siblings as healthy
reference subjects for biomarker scaling (see supporting information).
Subject inclusion requiredavailability of baseline3TT1-structuralMRI,
amyloid-PET (PiB), FDG-PET, and CSF data. No selection bias (ie, for
age, sex, education) was found between the included and non-included
subjects. EYO were defined as the difference between a participant’s
age at examination and the parental age of symptom onset. All partic-
ipants provided written informed consent; local ethical approval was
obtained at each participating DIAN site.
2.1.2 Alzheimer’s Disease Neuroimaging Initiative
(ADNI)
Three hundred ninety-one individuals meeting Petersen criteria for
amnestic MCI were included from ADNI, based on availability of
baseline 3T T1-structural MRI, amyloid-PET (AV45), FDG-PET, CSF,
and cognitive data (ie, ADNI-MEM and ADAS13), plus at least one
(and up to four) annually consecutive cognitive follow-up assess-
ments. No selection bias for age, sex, or education was found between
the included and non-included ADNI subjects. A𝛽-status was deter-
mined using a pre-established global AV45-PET standard uptake value
ratio (SUVR) cut-off of 1.11.30 Cognitively normal A𝛽+ subjects were
not included, due to the few subjects meeting our inclusion criteria
(N = 50/46/8/0 with 1/2/3/4-year follow-up). As a healthy refer-
ence group for biomarker scaling, we included baseline data of 49
RESEARCH INCONTEXT
1. Systematic review: Prodromal Alzheimer’s disease (AD)
patients are at increased risk to develop AD dementia.
However, there are considerable differences in cogni-
tive decline rates between individuals, posing challenges
for clinical prognostication. While AD biomarkers are
established for diagnostics, there is an unmet need of
biomarker models for predicting the rate of future cogni-
tive decline.
2. Interpretation: Machine learning applied to complex AD
biomarker data (ie, neuroimaging and biofluid) accurately
predicted estimated symptom onset in autosomal-
dominant Alzheimer’s disease and generalized well
to an independent sample of sporadic AD patients
for predicting 1- to 4-year cognitive decline. Machine
learning–based selection of at-risk patients with sporadic
prodromal AD significantly reduced numbers required
for detecting intervention effects by up to 50% to 75%.
These findings suggest that machine learning may help
derive meaningful prognostic indices from increasingly
complex biomarker data.
3. Future direction: Does the addition of tau-positron emis-
sion tomography and neuroinflammatory biomarkers fur-
ther increase prediction accuracy of future cognitive
decline?
cognitively normal A𝛽-negative (ie, global AV45-PET SUVR<1.11) sub-
jects below the age of 70 scoring >28 on the Mini-Mental State Exam
(MMSE).
2.2 Neuroimaging and biomarker assessment
Neuroimaging in DIAN and ADNI was performed using similar proto-
cols initially developed for ADNI. Structural MRI has been recorded on
3T scanners with a spatial resolution of 1.1 × 1.1 × 1.2 mm. FDG-PET
has been acquired consistently in both samples (ie, 30 to 60 minutes
after tracer injection, SUVR normalization to the brainstem), whereas
Amyloid-PET scanning has been conducted using PiB in DIAN (40–
70 minutes after tracer injection, SUVR normalized to the whole cere-
bellum) andAV45 inADNI (50–70minutes after tracer injection, SUVR
normalized to the whole cerebellum). All ADNI31,32 and DIAN29 imag-
ing protocols have been described previously. For the current study,
we used FreeSurfer-processed (Version 5.1) region of interest (ROI)
data (ie, cortical thickness and subcortical volumes for structural MRI
and SUVR values for PET) provided by theDIAN andADNI neuroimag-
ing cores. CSF concentrations of A𝛽1-42, phosphorylated tau at threo-
nine181 (p-tau181), and total tauweremeasuredby theusingmultiplex
xMap Luminex inDIANand via the Elecsys cobas e 601 instrument33 in
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F IGURE 1 Flow-chart of the support vector regression (SVR) analysis pipeline. (A) Selected data from the DIAN-MC and ADNI-MCI sample
are standardized and variance normalized to the respective healthy reference groups to ensure comparability of biomarker scaling across samples.
(B) The SVRmodel is trained based on selectedmodalities in DIAN-MC in a nested cross-validation framework. (C) The trained SVR-models are
blindly applied to the scaled ADNI-MCI biomarker data yielding a SVR score per subject. The SVR score is then evaluated as a predictor of baseline
cognition and longitudinal cognitive decline in ADNI
ADNI. Details on biomarker assessments can be found in the support-
ing information.
2.3 DIAN—support vector regression training
and nested cross-validation
Machine-learning analysiswas conductedusingNeuroMiner, aMatlab-
based machine-learning toolbox (www.pronia.eu/neurominer).34,35
In DIAN, we applied SVR to the neuroimaging/biomarker values
to predict EYO as a proxy of future cognitive decline. Prior to SVR
analysis, all biomarker/neuroimaging values were scaled to a healthy
reference sample within the ADNI and DIAN cohort, to yield compara-
bly interpretable values across samples (see Figure 1A and supporting
information). SVR training in DIAN (see Figure 1B) was conducted via
repeated nested CV to obtain an unbiased SVR performance estimate
in data unseen during SVR training. To this end, the DIAN MC group
was randomly divided into 10 subsamples (ie, outer CV2-folds). During
10 iterations, a respective outer CV2 test fold was held out, while the
remaining nine outer CV2-folds were pooled as SVR training data,
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and randomly divided into 10 subsamples (inner CV1-folds). For 10
iterations, a respective inner CV1 test fold was held out, while the
remaining inner CV1 data were used for SVR parameter tuning. The
trained SVR parameters were then applied to the held-out inner CV1
test fold to estimate prediction performance in yet unseen data. For
each CV1 iteration, the optimal SVRmodel was selected based on CV1
prediction performance (ie, minimum mean squared error between
actual and SVR-predicted EYO). Last, the selected inner CV1 models
were applied to the held-out outer CV2 test fold to estimate the mean
CV2 prediction performance. This nested CV approach was comple-
mented by repeated double CV, including 10-fold random permutation
of the DIANMC sample and repeating the above-described procedure
for each permutation for CV1 and CV2 levels.36 Together, feature
selection and parameter optimization were performed on the CV1
level, while final SVR prediction performance was assessed exclusively
on CV2 test folds unseen during SVR training (Figure 1B).
To extract the most predictive features (ie, imaging ROI values and
CSF data), we performed feature selection at the CV1 level retaining
the top 35% of features showing the highest Spearman correlation (ie,
to minimize the influence of extreme values or skewed data) with EYO.
Overall feature selection probability was defined as the likelihood of a
given feature tobe includedacross all optimalCV1models. Altering the
feature selection threshold between 25% and 45% did not change the
overall result pattern reported below.
2.4 Out-of-sample validation in ADNI
For our main analysis, we applied the 10000 ADAD-trained optimal
CV1 SVR models to the ADNI MCI biomarker data, and computed the
mean SVR score across all CV1models, which we hypothesized to pre-
dict future cognitive decline (see Figure 1C).
2.5 Statistics
Baseline measures were compared between groups using chi-squared
tests for categorical variables and analysis of variance (ANOVAs;
ADNI) or two-sample t tests (DIAN) for continuousmeasures.
In DIANMC, we estimated SVR prediction performance for all pos-
sible modality combinations, by assessing Pearson-moment correla-
tions between actual and SVR-predicted EYO. Feature selection prob-
abilities were visualized for the SVR model including all modalities (ie,
CSF [C], Amyloid-PET [A], FDG-PET [F], and GM [G]).
Next, we assessedwhether SVR scores predicted baseline cognition
or cognitive decline in the ADNI MCI validation sample. As measures
of interest, we used ADNI-MEM, an established memory composite
and ADAS13, a measure of global cognition.37 Subject-specific cogni-
tive change slopes were determined by fitting subject-specific linear
models with ADNI-MEM or ADAS13 scores as the dependent variable
and time from baseline as the independent variable. Annual cognitive
changes were estimated for baseline to year 1, year 2, year 3, or year
4 for those subjects who had complete annual clinical follow-up data,
respectively. Using linear models controlled for age, sex, and educa-
tion, we testedwhether higher SVR scores predicted (1) stronger base-
line cognitive impairment and (2) faster cognitive decline across 1- to
4-year follow-up. In an additional step, we included baseline cognition
as a covariate toassesswhether SVRscorespredicted cognitivedecline
after accounting for baseline symptom severity. Analyses in ADNIMCI
were stratified by A𝛽-status to test whether SVR–based prediction of
cognition is specific forMCI-A𝛽+ subjects.
Last, we tested whether SVR-based selection of MCI-A𝛽+ subjects
at risk of cognitive decline enhances the sensitivity to detect interven-
tion effects. Using linear mixed models, we assessed the main effect of
time from baseline on cognition (ie, ADNI-MEM or ADAS13) for the
entire MCI-A𝛽+ sample, or for SVR-selected subsamples of MCI-A𝛽+
subjects at highest risk of cognitive decline (ie, showing above median
SVR scores), controlling for age, sex, education, and random intercept.
Following previous work,38 sample size estimates were calculated on
group-mean cognitive changes (ie, ADNI-MEMorADAS13),with hypo-
thetical 10%/20%/30%/40% intervention effects using the R-package
pwr (settings: two-sample t test, two-tailed, type I error rate = 0.05,
power = 0.8). Analyses were conducted for the best-performing SVR
models with one, two, three, or four modality combinations for 1- to
4-year follow up.
All statistical analyses were performed in R statistical software.
Effects were considered significant at a two-tailed alpha threshold of
0.05.
3 RESULTS
Baseline characteristics of the study samples are presented in Table 1.
3.1 SVR training and cross-validation in ADAD
The SVRmodel trained on all availablemodalities (ie, amyloid [A], FDG-
PET [F], gray matter [G], CSF [C], abbreviated as AFGC) in DIAN MC
accurately predicted EYO at the CV2 level (r = 0.726, P <0.0001,
R2 = 0.53, Figure 2A). This model also showed the numerically high-
est predictive performance of EYO, compared to all other possible
modality combinations (Table S1 in supporting information). For the
AFGC model, we mapped the feature selection likelihood for each
modality (Figure 2B). For amyloid-PET, almost the entire neocortex
showed a high feature selection probability (ie, > 90%). For FDG-PET
predominantly medial and lateral parietal and lateral frontal, ROIs
showed high feature selection probability. For GM, mainly medial and
lateral parietal and medial temporal, ROIs such as the hippocampus
showed high feature selection probabilities. For CSF, p-tau181 showed
the highest selection probability, followed by total tau and A𝛽1−42.
When restricting biomarker modalities for SVR training, the best-
performing models for EYO prediction were AFG for three modalities
(r = 0.703, P <0.0001, R2 = 0.49), AG for two modalities (r = 0.677,
P<0.0001, R2 = 0.46), and G for single modality (r= 0.628, P<0.0001,
R2 = 0.39).
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TABLE 1 Baseline demographics
DIAN
MC
(N= 121)
NC (healthy
reference)
(N= 54) P
Age 38.66 (9.98) 38.87
(10.48)
0.8998
Sex (m/f) 49/72 19/35 0.5056
Education 14.27 (3.02) 15.50 (2.23) 0.0081
MMSE 27.74 (7.88) 30.00 (0.00) 0.0365
Logical-
memory
11.44 (5.9) 15.78 (3.45) <0.0001
EYO −7.10
(11.23)
−9.35
(10.94)
0.2185
ADNI
MCI-A𝜷+
(N= 216)
MCI-A𝜷−
(N= 175)
CN (healthy
reference)
(N= 49) P
Age 72.74 (6.69) 70.16 (7.76) 65.76 (2.69) <0.0001
Sex (m/f) 117/99 94/81 23/26 0.6345
Education 16.00 (2.79) 16.47 (2.47) 17.14 (2.27) 0.0139
MMSE 27.68 (1.83) 28.54 (1.44) 29.51 (0.51) <0.0001
ADAS13 17.18 (6.96) 12.21 (5.48) 6.24 (3.83) <0.0001
ADNI-MEM 0.11 (0.63) 0.62 (0.63) 1.46 (0.61) <0.0001
Values are displayed as mean (standard deviation). P-values for group com-
parisons are derived from two-sample t tests for DIAN and ANOVAs for
ADNI for continuous measures and Chi-squared tests for categorical mea-
sures. Abbreviations: EYO, estimated years to symptom onset; MC, muta-
tion carrier; MMSE,Mini-Mental State Exam; NC, non-carrier
3.2 Independent validation in ADNI—Predicting
cognitive decline inMCI-A𝜷+
Next, we applied the ADAD-trained SVR model on all modalities (ie,
AFGC) to ADNI MCI biomarker data. As hypothesized, greater AFGC
scores predicted lower baseline ADNI-MEM (t(211) = −6.692, 𝛽 =
−0.410, P <0.0001) and ADAS13 scores (t(211) = 5.615, 𝛽 = 0.355,
P <0.0001) in the MCI-A𝛽+ group but not in MCI-A𝛽− (ADNI-MEM:
t(170) = −0.239, 𝛽 = −0.017, P =0.812; ADAS13: t(170) = 0.457, 𝛽 =
0.035, P= 0.649).
Most importantly, we found higher AFGC scores in MCI-A𝛽+ to
predict faster decline in ADNI-MEM consistently across all follow-
up intervals, from baseline to year 1 (t(211) = −4.547, 𝛽 = −0.312,
P<0.0001, Figure 3A), year 2 (t(179)=−4.954, 𝛽 =−0.361, P<0.0001,
Figure 3B), year 3 (t(140)=−5.240, 𝛽 =−0.425, P<0.0001, Figure 3C),
and year 4 (t(100) = −5.317, 𝛽 = −0.502, P <0.0001, Figure 3D) where
partial R2-values increased for longer follow-up durations. Similarly,
higherAFGCscores predicted decline inADAS13 frombaseline to year
1 (t(211) = 2.337, 𝛽 = 0.355, P = 0.0204, Figure 3E), year 2 (t(179) =
4.510, 𝛽 = 0.334, P <0.0001, Figure 3F), year 3 (t(140) = 4.756, 𝛽 =
0.391, P <0.0001, Figure 3G), and year 4 (t(100) = 5.143, 𝛽 = 0.492,
P <0.0001, Figure 3H). No association was found between SVR scores
and cognitive changes in MCI-A𝛽-suggesting specificity for A𝛽+ sub-
jects. All results are summarized in Table 2. Further, all above-listed
results remained consistent when additionally controlling for baseline
cognition (ie, ADNI-MEM or ADAS13), suggesting that AFGC scores
predict cognitive decline independent of baseline symptom severity
(see Table S2 in supporting information).
3.3 SVR-based selection ofMCI-A𝜷+ at risk of
decline enhances the sensitivity to detect intervention
effects
Next, we tested whether SVR-based selection of MCI-A𝛽+ subjects
at highest risk of cognitive decline (ie, defined as falling above the
SVR score median) enhances the sensitivity to detect potential inter-
vention effects. We first determined the main effect of time on
longitudinal cognition (ADNI-MEM or ADAS13) in the unselected
MCI-A𝛽+ versus SVR-selected subsamples using linear mixed mod-
els, controlling for age, sex, education, and random intercept. Using
the annual cognitive change scores, we estimated the required sam-
ple sizes to detect intervention effects of 10% to 40% at 1- to 4-year
follow-up with an alpha of 0.05 at a power of 0.8. For the unselected
MCI-A𝛽+ sample,we found small but significantADNI-MEMdecreases
across 1-year follow-up (𝛽 = −0.052, P <0.0001, R2 = 0.01). The sam-
ple size per arm to detect 10%/20%/30%/40% reduction in cognitive
decline was 18984/4301/1737/892. In “at-risk” subjects with above
median AFGC scores, we found a stronger effect of time on ADNI-
MEM (𝛽 = −0.109, P <0.0001, R2 = 0.053). Here, the required N to
detect 10%/20%/30%/40% reduction in cognitive decline was greatly
reduced to 3375/765/310/159. Congruent results were found when
performing these analyses for longer follow-up durations or for the
best-performing three-modality, two-modality, and one-modality SVR
models (AGC, AG, or G) for selection of at-risk subjects (see Table 3).
Congruent results were also found when conducting all above-listed
analyses using ADAS13 as measure of cognition (Table 3). Together,
SVR-based “at-risk” selection may greatly reduce the required sample
size to detect intervention effects.
4 DISCUSSION
Our major aim was to establish a biomarker-based machine-learning
model for point prediction of AD-related cognitive decline. Our first
main finding was that machine-learning (ie, SVR) models trained for
predicting future symptom manifestation in ADAD (ie, EYO) general-
ize well to sporadic AD, where we found high prediction accuracy for
1- to 4-year global cognitive and memory decline. Second, we show
that SVR-based selection of sporadic AD subjects at highest risk for
cognitive decline can drastically reduce patient numbers required for
detecting intervention effects, even when using unimodal biomarkers.
Together, our findings suggest that ADAD-informed and biomarker-
basedmachine learning can accurately predict cognitive decline in spo-
radic AD and can be helpful for subject stratification in clinical trials.
Our findingsmake a significant contribution for identifying subjects
at risk of imminent cognitive decline. Our results are validated across
two independent and deeply phenotyped cohorts. A strength of the
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F IGURE 2 SVR-based prediction of EYO in autosomal-dominant Alzheimer’s disease and feature selection probabilities. (A) Scatterplot show-
ing the association between observed EYO scores and AFGC-predicted estimated years to symptom onset (EYO) scores in DIAN-MC. (B) Selection
probabilities of the AFGCmodel indicate the percentage of final CV1models (see step in Figure 1B) that included the respective region of inter-
est/biomarker. Features were selected in theDIAN-MC cohort during each CV1 cycle based on the correlationwith the outcomemeasure (ie, EYO)
study is that we chose ADAD for model training, as those subjects are
relatively young and age-related comorbidities (eg, small-vessel dis-
ease) are minimal.39 This allowed extracting AD-specific brain changes
that occur early in the disease course. We acknowledge differences
between ADAD and sporadic AD including earlier symptom onset,
higher likelihood of non-memory symptoms,40 and higher prevalence
of psychiatric comorbidities41 in ADAD versus sporadic AD. However,
both sporadic AD and ADAD share core neuropathological features
and biomarker abnormalities including amyloid and tau accumulation,
FDG-PET hypometabolism, and neurodegeneration.28,41 Importantly,
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F IGURE 3 SVR-based prediction of cognitive changes in ADNIMCI-A𝛽+. Scatterplots showing the association between AFGC-derived SVR
scores and longitudinal cognitive change in ADNI-MCI-A𝛽+ for ADNI-MEM (A-D) and ADAS13 (E–H). Standardized 𝛽-values, partial R2, and
P-values are based on linear regressionmodels adjusted for age, sex, and education
TABLE 2 Prediction of baseline cognition and longitudinal
cognitive changes in ADNIMCI-A𝛽+
ADNIMCI-A𝜷+
N 𝜷 T P Partial R2
ADNI-MEM
Baseline 216 −0.410 −6.692 <0.0001 0.168
Year 1 216 −0.312 −4.547 <0.0001 0.097
Year 2 184 −0.361 −4.954 <0.0001 0.130
Year 3 145 −0.425 −5.240 <0.0001 0.180
Year 4 105 −0.502 −5.317 <0.0001 0.252
ADAS-13
Baseline 216 0.355 5.615 <0.0001 0.126
Year 1 216 0.168 2.337 0.0204 0.028
Year 2 184 0.334 4.510 <0.0001 0.112
Year 3 145 0.391 4.746 <0.0001 0.153
Year 4 105 0.492 5.143 <0.0001 0.242
All regressionmodels were controlled for age, sex, and education.
the emergence of cognitive symptoms in ADAD is driven byADpathol-
ogy rather than age-related comorbidities, and thus, provides a good
model for AD-related cognitive decline.27,42
The most predictive features in amyloid-PET included almost the
entire neocortex, sparing primary sensorimotor, and medial tempo-
ral regions that develop amyloid very late in AD.43,44 Further, predic-
tive regions included posterior parietal and medial temporal regions
for MRI and posterior parietal and lateral frontal regions for FDG-
PET, that is, AD-typical predilection sites. Furthermore, the prediction
of cognitive decline was non-significant in MCI-A𝛽- and was indepen-
dent of confounding factors including age, sex, education, or baseline
cognition. Together, these findings support the validity of our predic-
tionmodel to depend on key AD-related brain changes.
Previous studies evaluating biomarker combinations9,12 or
machine learning demonstrated that biomarker combinations can
enhance the accuracy of predicting cognitive decline or conversion to
dementia.20,21 Consistently, we found increasing prediction accuracy
as model estimation was informed by more biomarker modalities. We
guarded against overfitting by first training and cross-validating the
machine-learning algorithmonADAD,41 with subsequent independent
validation in sporadic AD. Importantly, in sporadic AD, we found that
biomarker-based risk enrichment led to drastically lower sample sizes
required to detect intervention effects with cognitive decline as an
endpoint. This finding has several implications: First, screening exami-
nations that are frequently used in intervention trials (eg, amyloid-PET
andMRI) can be used to enrich for “at-risk” subjects to enhance power
and reduce subject numbers and costs for interventions45 or to assess
whether intervention effects depend on individual progression risk.46
Together, knowledge of individual risk for cognitive decline may be
used for more adaptive and cost-efficient intervention research, which
is urgently needed in view of numerous failed clinical trials in AD.47
However, several caveats should be considered when interpreting
our results: First, DIAN and ADNI differ in inclusion criteria (ADAD
vs sporadic AD) and data acquisition protocols (ie, MRI hardware, PET
tracers, and CSF immunoassays), reducing comparability across stud-
ies. To address this, we a priori adjusted all biomarker data to healthy
control subjects within each study, to obtain harmonized and compa-
rably interpretable values. Importantly, however, rather than pooling
data across ADNI and DIAN, where variability across the two studies
may hamper model estimation, we used an independent-validation
approach for assessing external validity of the ADAD-trained SVR
models. The high generalizability from ADAD to sporadic AD supports
the robustness and external validity of the SVR models, suggesting
that our findings are not driven by assessment procedures or study
selection criteria.
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TABLE 3 Sample size estimation for detecting intervention effects based on unselectedMCI-A𝛽+ subject or on SVR selection of at-risk
subjects (defined as falling above themedian of SVR scores)
Main effect of time on cognitive changes in
MCI-A𝜷+
Required N per arm to detect an
intervention effect of
Cognitive test
Group
selection 𝜷 T P
Partial
R2 10% 20% 30% 40%
%Reduction
of required N
1-year follow-up
ADNI-MEM No selection −0.052 −4.021 <0.0001 0.010 18984 4301 1737 892 NA
G-risk −0.084 −4.703 <0.0001 0.028 6937 1572 635 327 63%
AG-risk −0.090 −5.170 <0.0001 0.033 5742 1301 526 271 70%
AGC-risk −0.095 −5.574 <0.0001 0.037 4940 1120 458 233 74%
AFGC-risk −0.109 −6.744 <0.0001 0.053 3375 765 310 159 82%
ADAS13 No selection 0.037 1.764 0.0792 0.002 94800 21475 8672 4453 NA
G-risk 0.070 2.317 0.0224 0.008 27638 6261 2529 1299 71%
AG-risk 0.073 2.326 0.0219 0.009 27392 6205 2506 1287 71%
AGC-risk 0.089 2.933 0.0041 0.013 17335 3927 1586 815 82%
AFGC-risk 0.100 3.149 0.0021 0.016 15086 3418 1381 709 84%
2-year follow-up
ADNI-MEM No selection −0.076 −6.425 <0.0001 0.026 9166 2077 839 431 NA
G-risk −0.131 −8.071 <0.0001 0.080 2741 622 252 130 70%
AG-risk −0.136 −8.372 <0.0001 0.085 2574 584 236 122 72%
AGC-risk −0.140 −8.862 <0.0001 0.095 2370 538 218 112 74%
AFGC-risk −0.144 −8.850 <0.0001 0.097 2293 520 211 109 75%
ADAS13 No selection 0.122 6.421 <0.0001 0.031 8748 1982 801 412 NA
G-risk 0.178 6.208 <0.0001 0.060 4360 988 400 206 50%
AG-risk 0.178 6.137 <0.0001 0.060 4545 1030 417 214 48%
AGC-risk 0.199 6.957 <0.0001 0.075 3526 799 323 166 60%
AFGC-risk 0.209 7.160 <0.0001 0.081 3410 773 313 161 61%
4-year follow-up
ADNI-MEM No selection −0.173 −10.755 <0.0001 0.107 3857 874 354 182 NA
G-risk −0.264 −12.331 <0.0001 0.250 1348 306 124 64 65%
AG-risk −0.291 −14.188 <0.0001 0.307 905 206 84 43 76%
AGC-risk −0.294 −14.303 <0.0001 0.318 900 205 83 43 76%
AFGC-risk −0.264 −12.694 <0.0001 0.256 1295 294 119 62 66%
ADAS13 No selection 0.239 10.750 <0.0001 0.118 3818 866 350 180 NA
G-risk 0.325 10.943 <0.0001 0.222 1778 404 163 84 53%
AG-risk 0.356 11.921 <0.0001 0.348 1462 332 135 69 62%
AGC-risk 0.369 11.919 <0.0001 0.262 1441 327 133 68 62%
AFGC-risk 0.338 11.302 <0.0001 0.235 1728 392 159 82 54%
Second, the sporadic AD group was restricted to MCI; hence,
it remains open whether our findings generalize toward earlier AD
stages. However, previous studies have shown that preclinical AD sub-
jects show only little cognitive change across 1- to 4-year follow-up
intervals;48 hence,we reason that longer follow-ups and large numbers
currently unavailable in ADNI are required to test whether the SVR
model can predict cognitive changes in preclinical AD.
Third, we trained the model on EYO in ADAD, which is only a cross-
sectional proxy of future cognitive decline.27 Computing actual cog-
nitive decline in ADAD would have drastically reduced the sample
size to those with available longitudinal cognitive data. To maximize
sample size, which is critical for training and CV of machine-learning
models within the ADAD group, we thus preferred to use cross-
sectional data.49 When sufficient longitudinal data become available
in DIAN, future studies may assess whether SVR performance can be
further improvedwhen the SVRmodel is trained on actual longitudinal
cognitive decline.
Fourth, due to limited data availability, we did not include tau-
PET, which has been recently shown to be a good predictor of
future cognitive decline in AD.15 However, we included measures of
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tau-related pathology (ie, CSF), which have been previously shown to
correlate with the level of tau-PET uptake50 and to predict future cog-
nitive decline.9 Nevertheless, inclusion of tau-PET in the SVR model
may improve prediction of cognitive decline. Here, our methodologi-
cal framework will easily allow us to include tau-PET as an additional
modality as soon as large enough data become available.
Together, we show that ADAD-informed machine learning can be
powerful for point prediction of future cognitive decline in sporadic
AD. These findings have important implications because our proposed
SVRmodelsmayhelpderive single prognostic indices from increasingly
complex biomarker data. The proposed models allow flexible inclusion
of various biomarkers, rendering them highly adaptable to individual
cohorts. To enhance the external validity of our proposed SVRmodels,
it will be of special importance in the future to determine their pre-
diction performance also across less selective and community-based
samples, as well as across different biomarker combinations and acqui-
sition protocols. Our findings may be critical for clinical AD research
to identify subjects at risk for progression and to evaluate therapeutic
interventions for future cognitive decline.
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